10-K: Astrana Health Reports Strong Revenue Growth Amidst Key Acquisition

Astrana Health's 2025 annual report highlights significant revenue and Adjusted EBITDA growth driven by strategic acquisitions, despite a decline in net income and an identified material weakness in internal controls.

Summary

• Total revenue for 2025 increased by 56% to $3,181.8 million, up from $2,034.5 million in 2024.
• Capitation revenue, net, grew by 57% to $2,924.3 million in 2025, compared to $1,856.8 million in 2024.
• Adjusted EBITDA increased by 21% to $205.4 million in 2025, from $170.4 million in 2024.
• Net income attributable to Astrana Health, Inc. decreased by 48% to $22.5 million in 2025, down from $43.1 million in 2024.
• Operating income decreased by 12% to $78.5 million in 2025, from $89.4 million in 2024.
• The company completed the acquisition of certain businesses and assets of Prospect Medical Holdings, Inc. (Prospect) on July 1, 2025, for $674.9 million, contributing approximately $616.3 million in revenue.
• As of December 31, 2025, Astrana Health managed care for approximately 1.6 million patients, up from 1.1 million in 2024, and expanded its network to over 20,000 contracted physicians.
• A material weakness in internal control over financial reporting was identified related to accounting for business combinations, specifically the completeness and accuracy of net working capital determination.
• The company increased its share repurchase program authorization to $100.0 million in February 2026, with $35.9 million remaining as of December 31, 2025.
• Cash provided by operating activities increased by 120% to $114.6 million in 2025, from $52.2 million in 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with mixed sentiment. While significant revenue and Adjusted EBITDA growth driven by strategic acquisitions are positive, the substantial decline in net income and the identified material weakness in internal controls present notable concerns, balancing the overall outlook.

Positives

• Total revenue increased significantly by 56% to $3,181.8 million in 2025, primarily driven by the Prospect Acquisition.
• Capitation revenue, a core revenue stream, saw a substantial 57% increase to $2,924.3 million.
• Adjusted EBITDA grew by 21% to $205.4 million, indicating improved operational performance before non-recurring and non-cash items.
• Adjusted EPS diluted increased to $2.20 in 2025 from $1.94 in 2024, reflecting better earnings per share on an adjusted basis.
• Free cash flow more than doubled, increasing by 136% to $104.5 million in 2025, demonstrating strong cash generation from operations.
• The Prospect Acquisition significantly expanded the provider network and enhanced the ability to offer increased access, quality, and value to members.
• The company expanded its patient base to approximately 1.6 million and its physician network to over 20,000 contracted physicians as of December 31, 2025.
• New partnerships with a Southern California provider group and Intermountain Health in Southern Nevada aim to expand access to coordinated, high-quality care and advance healthcare infrastructure.
• The share repurchase program was increased to $100.0 million, signaling confidence in the company's valuation and commitment to shareholder returns.

Negatives

• Net income attributable to Astrana Health, Inc. decreased significantly by 48% to $22.5 million in 2025, from $43.1 million in 2024.
• Income from operations decreased by 12% to $78.5 million in 2025, from $89.4 million in 2024, primarily due to higher utilization and increased general and administrative expenses.
• Adjusted EBITDA margin decreased to 6% in 2025 from 8% in 2024, indicating a reduction in profitability relative to total revenue on an adjusted basis.
• Interest expense increased by 51% to $49.9 million in 2025, primarily due to increased borrowings under the Second Amended and Restated Credit Facility to finance the Prospect Acquisition.
• Working capital decreased by $24.9 million to $248.0 million at December 31, 2025, from $272.9 million at December 31, 2024.
• The company's total debt increased substantially to $1,052.2 million as of December 31, 2025, from $438.1 million as of December 31, 2024, largely due to the Prospect Acquisition financing.
• Medical liabilities increased to $335.7 million in 2025 from $209.0 million in 2024, reflecting increased responsibility for claims.
• The company recorded a $13.0 million loss contingency in the third quarter of 2025 related to a legal matter with a provider associated with CFC Health Plan, Inc.

Risks

• The Prospect Acquisition resulted in a material increase in indebtedness, potentially reducing business flexibility and increasing interest expense.
• Difficulties in integrating Prospect's operations could disrupt current plans, business, or results, and anticipated cost synergies may not be fully realized.
• The acquisition of a hospital (Foothill Regional Medical Center) is a new business for Astrana, posing additional operational challenges and risks.
• Potential additional costs and expenses may arise from the July 7, 2025, bankruptcy of certain Prospect asset-seller entities.
• The company may need to raise additional capital to grow, which might not be available on favorable terms or at all, potentially leading to significant dilution for existing shareholders.
• Uncertain or adverse economic conditions (e.g., inflation, variable interest rates, supply chain/labor disruptions, geopolitical events) could negatively impact the business.
• Changes in accounting principles or their interpretation affecting the consolidation of Variable Interest Entities (VIEs) could impact reported revenues.
• Arrangements with VIEs are not as secure as direct ownership, and failure of affiliated entities or their equity holders to perform could have a material adverse effect.
• A substantial portion of revenues are derived from California, making the company vulnerable to changes in state-specific regulations or economic conditions.
• The company's complex legal structure may lead tax authorities to question tax positions, potentially resulting in unanticipated costs (e.g., IRS examination for 2019-2022 tax returns).
• Net operating loss carryforwards and other tax attributes may be subject to limitations under Section 382 of the Internal Revenue Code.
• Difficulties in managing rapid growth could strain human and capital resources and impede successful execution of business plans.
• Significant losses could occur under capitation contracts if medical expenses exceed revenues, especially with potential rate adjustments like those mandated by California's AB 118.
• Dependence on a limited number of key payers (four payers accounted for 59.8% of total net revenue in 2025) creates concentration risk.
• A shift in payer mix from private insurance to lower-paying government programs or uninsured patients could reduce reimbursement rates and increase uncollectible receivables.
• Many agreements with hospitals and medical groups have limited durations, may be terminated without cause, and can restrict the company's ability to acquire physicians or patients.
• The healthcare industry is intensely regulated, and non-compliance with federal, state, and local laws could result in significant penalties or operational changes.
• Medicaid, Medicare, or Marketplace capitation rates may be insufficient to cover medical care costs, and legislative changes (e.g., OBBBA, Medicare Advantage Rate Adjustments) could negatively impact programs.
• Breaches or compromises of information security systems, including those of third-party vendors, could expose private information, disrupt business, and damage reputation, with increasing risks from AI-driven cyberattacks.
• The success of participation in ACO REACH Model or other CMS Advanced Alternative Payment Models is not guaranteed due to program uncertainties, political risks, and responsibility for out-of-network provider costs.
• Competition for qualified physicians, employees, and management personnel is intense, potentially leading to higher labor costs or an inability to maintain a robust network.
• Loss of key management personnel (e.g., CEO Brandon K. Sim, CFO/COO Chandan Basho) could materially adversely affect business operations.
• Assets held at financial institutions exceeding FDIC insurance coverage (approximately $447.0 million as of December 31, 2025) pose a liquidity risk in case of bank failure.
• The company may face lawsuits not covered by insurance, and related expenses could be material, potentially impacting financial condition and cash flows.
• Compliance with non-healthcare specific laws and regulations (e.g., climate disclosure, AI regulations, California Finance Lenders Law) could require significant expenditures and management time.

Future Outlook

Management anticipates that the One Big Beautiful Bill Act (OBBBA) will not have a material impact on tax expense in 2025 and views the policy changes as manageable due to Astrana's diversified footprint, strong Medicaid performance, and care-enablement infrastructure. Regarding the proposed 2027 Medicare Advantage payment rates, the company expects the impact of risk adjustment model changes to be materially less significant for Astrana than for the broader Medicare Advantage market, expressing confidence in its position to navigate these changes. The company plans to continue extending leases and leasing additional facilities to accommodate future growth and will continue to pursue strategic opportunities, both organically and through acquisitions or alliances.

Management Comments

• "Astrana is well-positioned to navigate these changes and view these headwinds as manageable." (referring to OBBBA and 2027 Medicare Advantage payment rates)
• "Our diversified footprint, strong track record of Medicaid performance, and investment in care-enablement infrastructure provide meaningful insulation." (regarding the OBBBA's impact)
• "We expect the impact of the proposed risk adjustment model changes to be materially less significant for Astrana than for the broader Medicare Advantage market." (regarding the 2027 Advance Notice from CMS)

Industry Context

StockSavvy.ai notes that Astrana Health's strategic moves, particularly the Prospect acquisition and partnerships, align with the broader healthcare industry trend towards consolidation and the shift to value-based and patient-centered care models. The company's focus on technology-powered care enablement positions it to capitalize on the growing demand for integrated healthcare information and efficient care delivery. The industry faces increasing U.S. healthcare expenditures, projected to reach $8.6 trillion by 2033, driving a continuous need for cost-effective, high-quality care. Regulatory changes, such as the OBBBA and evolving Medicare Advantage payment rates, reflect ongoing government efforts to control costs and reshape reimbursement, creating both opportunities and challenges for industry players. The Supreme Court's Loper Bright decision introduces uncertainty regarding agency deference, potentially increasing challenges to health regulators' decisions and impacting the speed of regulatory changes in the highly regulated healthcare sector. The increasing adoption of AI also presents both opportunities for efficiency and new cybersecurity and ethical risks across the industry.

Comparison to Industry Standards

• Astrana Health competes with national, regional, and local providers across its segments, including large players like Optum (a subsidiary of UnitedHealth Group) and Heritage Provider Network (which includes Regal Medical Group and Lakeside Medical Group) in the IPA space.
• In the ACO market, Astrana's ACOs compete with sophisticated provider groups such as Privia Health and Aledade, which also create, administer, and manage ACOs.
• For outpatient clinics, competitors include large ambulatory surgery centers and diagnostic centers like RadNet and Envision Healthcare, as well as smaller local clinics.
• The company's hospital competes with other hospitals in its geographic area, such as Hoag Health Center and University of California-Irvine Health.
• In the MSO space, Astrana's technology-powered MSOs compete with companies like Conifer Health Solutions, InnovAccer, Arcadia, Lightbeam Health Solutions, and Lumeris, which offer similar management and administrative services platforms.

Corporate Governance

Legal Proceedings

• The company was involved in an arbitration proceeding with a provider associated with CFC Health Plan, Inc. (CFC HP) alleging breach of contract and fraud related to purported failure to pay for services.
• The arbitration was resolved by settlement and dismissed in February 2026, with the company paying $12.0 million towards the settlement in 2025 and a final $1.0 million in January 2026.
• The company is seeking reimbursement for the loss from the CFC HP Arbitration through a claim to escrow funds, with no gain contingency recorded as of December 31, 2025.
• The company is generally subject to various lawsuits, threatened lawsuits, disputes, and other claims arising in the normal course of business, including potential malpractice lawsuits common in the healthcare industry.

Related Party Transactions

• The company incurred rent expense of approximately $4.7 million in 2025 from properties managed by Allied Pacific Holdings Investment Management, LLC, whose CEO is a board member.
• Operating right-of-use assets and lease liabilities included $10.1 million and $10.7 million, respectively, for properties managed by Allied Pacific Holdings Investment Management, LLC.
• The company incurred approximately $5.0 million in 2025 in expenses payable to Third Way Health for call center and credentialing services, where one of Astrana's officers is a board member.
• Astrana converted a $6.0 million SAFE with Third Way Health into common and preferred stock in December 2025, resulting in approximately 27.7% ownership.
• Revenue with AHMC (where one of the company's directors is an officer) was $21.5 million in 2025, while expenses incurred with AHMC were $165.7 million, resulting in a net loss of $144.2 million.
• The company recognized risk pool revenue of $13.8 million from a risk-sharing agreement with AHMC hospitals in 2025, with $40.5 million remaining outstanding.
• The company paid an aggregate of approximately $21.1 million in 2025 to board members for provider services, including $3.2 million to Astrana board members who are also board members and officers of APC.
• Intercompany loans are made with designated shareholder professional corporations where the sole shareholder is a member of the company's key personnel, due to corporate practice of medicine laws.

Stakeholder Impact

• Shareholders: Experience dilution risk from future equity issuances and potential volatility in stock price due to market conditions and company-specific factors. The share repurchase program could be positive, but no regular cash dividends are planned. The material weakness in internal controls could erode investor confidence.
• Employees: Benefit from professional development programs, competitive compensation, and a safe/inclusive workplace. The increase in workforce for Care Enablement indicates job growth. However, labor shortages in the healthcare industry could impact workload and retention.
• Patients: Benefit from expanded access to high-quality, coordinated care through the Prospect acquisition and new partnerships, as well as the company's integrated health network and population health management programs. Potential changes in government healthcare programs (e.g., Medicaid eligibility) could affect patient coverage.
• Providers (Physicians, Specialists, Hospitals): The company's physician-centric model aims to empower providers in value-based care. Acquisitions expand the network, but competition for qualified physicians remains intense. Regulatory compliance and potential changes in reimbursement rates directly impact providers.
• Creditors: The significant increase in indebtedness due to the Prospect acquisition and the Second Amended and Restated Credit Agreement increases financial risk, though the company believes it has sufficient liquidity. Covenants in credit agreements impose restrictions on operations.
• Regulatory Authorities: The company is subject to extensive federal, state, and local regulations. Non-compliance or changes in laws (e.g., corporate practice of medicine, False Claims Act, Anti-Kickback Statutes, HIPAA, AI regulations) could lead to penalties and operational restructuring.

Next Steps

• Remediate the identified material weakness in internal control over financial reporting by establishing a standardized acquisition checklist, implementing formal controls for acquired assets/liabilities, introducing a multi-tiered management review process, enhancing technical oversight, and providing mandatory technical training.
• Evaluate the full downstream effects of the One Big Beautiful Bill Act (OBBBA) and the proposed 2027 Medicare Advantage payment rates.
• Continue to pursue growth opportunities, both organically and through acquisitions or alliances with other medical service providers.
• Extend leases on various facilities as necessary and lease additional facilities to accommodate possible future growth.
• Monitor and adapt to evolving regulatory frameworks, including those related to artificial intelligence and climate disclosure laws.

Key Dates

Recommendation

Astrana Health's strong revenue and Adjusted EBITDA growth, driven by strategic acquisitions like Prospect, demonstrate significant expansion and market positioning in value-based care. However, the substantial decline in net income and the identified material weakness in internal controls introduce considerable uncertainty and execution risk. While management expresses confidence in navigating challenges and has a remediation plan, the increased debt load and integration complexities warrant a cautious approach. The stock is a 'hold' as the long-term strategic benefits need to materialize and the internal control issues must be effectively resolved before a more bullish stance can be taken. Investors should monitor the successful integration of acquired assets and the remediation of the material weakness.

Keywords

Healthcare, Value-Based Care, SEC Filing, 10-K, Astrana Health, ASTH, Managed Care, Physician Network, Acquisition, Prospect Medical Holdings, Capitation, Adjusted EBITDA, Net Income, Internal Controls, Material Weakness, Risk-Bearing Organization, ACO REACH, Medicare, Medicaid, Financial Performance, Debt Financing, Share Repurchase, Corporate Practice of Medicine, Cybersecurity, AI in Healthcare